[go: up one dir, main page]

BR0115986A - Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos - Google Patents

Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos

Info

Publication number
BR0115986A
BR0115986A BR0115986-0A BR0115986A BR0115986A BR 0115986 A BR0115986 A BR 0115986A BR 0115986 A BR0115986 A BR 0115986A BR 0115986 A BR0115986 A BR 0115986A
Authority
BR
Brazil
Prior art keywords
active ingredient
acid
rapidly disintegrating
tablet
disintegrating tablet
Prior art date
Application number
BR0115986-0A
Other languages
English (en)
Inventor
Rango Dietrich
Rudolf Linder
Hartmut Ney
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of BR0115986A publication Critical patent/BR0115986A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPRIMIDO DE DESINTEGRAçãO RáPIDA CONTENDO UM INGREDIENTE ATIVO INSTáVEL AOS áCIDOS". A invenção refere-se a um comprimido de desintegração rápida para administração oral de ingredientes ativos instáveis aos ácidos. O comprimido de desintegração rápida para administração oral de um ingrediente ativo instável aos ácidos contém uma multiplicidade de unidades individuais de ingrediente ativo juntamente com excipientes farmacêuticos, onde o ingrediente ativo instável aos ácidos está presente nas unidades individuais de ingrediente ativo em uma matriz composta de uma mistura contendo pelo menos uma parafina sólida e uma ou mais substâncias do grupo de álcool graxo, triglicerídeo e éster de ácido graxo e onde os excipientes que estão presentes na ingestão oral do comprimido, causam a desintegração do comprimido.
BR0115986-0A 2000-12-07 2001-12-06 Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos BR0115986A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126807 2000-12-07
PCT/EP2001/014340 WO2002045694A1 (en) 2000-12-07 2001-12-06 Rapidly disintegrating tablet comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
BR0115986A true BR0115986A (pt) 2003-12-23

Family

ID=8170591

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115986-0A BR0115986A (pt) 2000-12-07 2001-12-06 Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos

Country Status (16)

Country Link
US (1) US7147869B2 (pt)
EP (1) EP1341528B1 (pt)
JP (1) JP2004514737A (pt)
KR (1) KR20030072555A (pt)
CN (1) CN100335040C (pt)
AT (1) ATE541564T1 (pt)
AU (1) AU2002221939A1 (pt)
BR (1) BR0115986A (pt)
CA (1) CA2430829C (pt)
CY (1) CY1112615T1 (pt)
DK (1) DK1341528T3 (pt)
ES (1) ES2380654T3 (pt)
HK (1) HK1062264A1 (pt)
PT (1) PT1341528E (pt)
SI (1) SI1341528T1 (pt)
WO (1) WO2002045694A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
EP1341523B1 (en) * 2000-12-07 2013-01-23 Nycomed GmbH Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
AU2002231654A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical paste comprising an acid-labile active ingredient
CN100469366C (zh) * 2001-07-16 2009-03-18 阿斯特拉曾尼卡有限公司 包含质子泵抑制剂和抗酸剂的药物制剂
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PT1606261E (pt) 2003-03-10 2010-01-11 Nycomed Gmbh Novo processo para a preparação de roflumilast
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8057820B2 (en) * 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8758814B2 (en) * 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
EP1861074B1 (en) 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
DE202006020168U1 (de) * 2005-12-21 2008-07-17 Basf Se Pharmazeutische Formulierung für die Herstellung von schnell zerfallenden Tabletten
KR20160083132A (ko) * 2007-06-06 2016-07-11 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
EP2164460B1 (de) * 2007-06-06 2017-08-09 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
BRPI0818286A2 (pt) * 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
DE102010011421A1 (de) * 2009-03-19 2010-09-30 Schaeffler Technologies Gmbh & Co. Kg Schaltbarer Schlepphebel eines Ventiltriebs einer Brennkraftmaschine
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EP2544665A4 (en) * 2010-03-11 2014-01-01 Rich Vitamins Llc NUTRITIONAL POWDER WITH RAPID DISSOLUTION
EP2441446A1 (en) * 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Using of superdisintegrants in cetyl myristate and/or cetyl palmitate formulations
EP2589378A1 (en) * 2010-10-14 2013-05-08 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
EP2661254B1 (en) 2011-01-05 2017-08-02 Hospira, Inc. Spray drying vancomycin
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) * 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) * 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
ATE245023T1 (de) 1991-05-28 2003-08-15 Mcneil Ppc Inc Kaubare zusammensetzung zur arzneimittelfreisetzung
ATE253899T1 (de) * 1994-01-31 2003-11-15 Yamanouchi Pharma Co Ltd Intraoral löslicher formpressling und verfahren zu seiner herstellung
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
PT1078628E (pt) 1994-07-08 2009-01-27 Astrazeneca Ab Forma de dosagem em comprimidos com unidades múltiplas
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
JP4939680B2 (ja) * 1997-05-27 2012-05-30 武田薬品工業株式会社 固形製剤
PL197989B1 (pl) * 1997-12-19 2008-05-30 Smithkline Beecham Corp Sposób wytwarzania szybko rozpraszających się tabletek do podawania doustnego, szybko rozpraszający się preparat farmaceutyczny w postaci tabletek i szybko rozpraszająca się, farmaceutycznie dopuszczalna, tabletka do podawania doustnego
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
CN1195500C (zh) * 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
DK1100469T3 (da) * 1998-07-28 2005-04-18 Takeda Pharmaceutical Hurtigt henfaldende fast præparat
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
HUP0201637A3 (en) * 1999-06-07 2004-05-28 Altana Pharma Ag Novel preparation and administration form comprising an acid-labile active compound

Also Published As

Publication number Publication date
AU2002221939A1 (en) 2002-06-18
EP1341528B1 (en) 2012-01-18
EP1341528A1 (en) 2003-09-10
PT1341528E (pt) 2012-03-20
CN1479613A (zh) 2004-03-03
US20040110661A1 (en) 2004-06-10
WO2002045694A1 (en) 2002-06-13
CA2430829C (en) 2010-06-22
ES2380654T3 (es) 2012-05-17
HK1062264A1 (en) 2004-10-29
US7147869B2 (en) 2006-12-12
CN100335040C (zh) 2007-09-05
KR20030072555A (ko) 2003-09-15
CA2430829A1 (en) 2002-06-13
DK1341528T3 (da) 2012-03-26
SI1341528T1 (sl) 2012-05-31
CY1112615T1 (el) 2016-02-10
JP2004514737A (ja) 2004-05-20
ATE541564T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
BR0115986A (pt) Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos
DK1341527T3 (da) Farmaceutisk præparat omfattende et aktivstof dispergeret på en matrix
HUP0201637A2 (hu) Savval szemben labilis vegyületet tartalmazó új készítmény és adagolási forma
ATE334689T1 (de) Verabreichungsmedium für analgetische, entzündungshemmende und antipyretische wirkstoffe und pharmazeutische zusammensetzungen enthaltend solches medium und wirkstoffe
BR9908121A (pt) Forma galênica de liberação imediata e de liberação prolongada administrável por via oral compreendendo um agente estimulador de absorção e utilização deste agente estimulador de absorção
BRPI0009373B8 (pt) composições farmacêuticas orais contendo triglicerídeos de cadeia longa e tensoativos lipofílicos
DE50104138D1 (de) Injizierbare pharmazeutische zusammensetzung zur systemischen verabreichung pharmakologisch aktiver wirkstoffe enthaltend mittelkettige triglyceride
DE69809074D1 (de) Herstellung von arzneimitteln
KR880010759A (ko) 방출 조절성 제제
PT89467A (pt) Processo para a preparacao de novas formulacoes galenicas de libertacao programada
ES2228057T3 (es) Oregano para el tratamiento de parasitos internos y protozoos.
KR900012612A (ko) 제약 조성물
BR0109036A (pt) Formulações farmacêuticas
BR9508034A (pt) Processo e aparelhagem para a preparação de uma unidade comestível que se dissolve rapidamente a referida unidade composição para liberar um ingrediente ativo processo para administração de um ingrediente ativo a um hospedeiro humano e produto provisório para fabricação da unidade comestível
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.
HUP9700842A1 (hu) Hatóanyagok szabályozott felszabadulását biztosító, stabilizált lipofil mátrixalapú gyógyászati készítmények
KR890011594A (ko) 4-아로일이미다졸-2-온의 제약 조성물
Palmer et al. The effect of neurohumoral drugs on the fixation of spinal reflexes and the incorporation of uridine into the spinal cord
Antony et al. Effect of galangin on ethanol and cerulein induced inflammatory changes in pancreas: a biochemical study in rat model
KR20240049578A (ko) 트리카프릴린을 이용한 편두통 및 관련 두통 증상 치료 방법
JPS6485933A (en) Slow-releasing oral preparation composition
TH14737A (th) สารผสมทางเภสัชศาสตร์ที่คงตัวของอนุพันธ์ฟิวแมจิลลอล

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NYCOMED GMBH (DE)

Free format text: ALTERADO DE: ALTANA PHARMA AG

B25A Requested transfer of rights approved

Owner name: DR. RANGO DIETRICH (DE)

Free format text: TRANSFERIDO DE: NYCOMED GMBH

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.